Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73634064" target="_blank" >RIV/61989592:15110/25:73634064 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/article/10.1186/s10020-025-01392-2" target="_blank" >https://link.springer.com/article/10.1186/s10020-025-01392-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s10020-025-01392-2" target="_blank" >10.1186/s10020-025-01392-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies

Popis výsledku v původním jazyce

This study investigates the prognostic impact of multi-hit TP53 in patients with multiple myeloma treated in the era of novel therapeutic agents. Multi-hit TP53, defined as the presence of del(17p) combined with a TP53 mutation or at least two TP53 mutations, was analyzed in a real-world cohort of 204 patients. The results demonstrate that patients harboring multi-hit TP53 exhibit the poorest progression-free survival and overall survival compared with other high-risk cytogenetic groups and standard-risk patients. Multi-hit TP53 was associated with advanced disease stage and treatment resistance, highlighting its role as a critical adverse prognostic factor. These findings support the routine assessment of TP53 abnormalities for improved risk stratification and therapeutic decision-making in multiple myeloma.

Název v anglickém jazyce

Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies

Popis výsledku anglicky

This study investigates the prognostic impact of multi-hit TP53 in patients with multiple myeloma treated in the era of novel therapeutic agents. Multi-hit TP53, defined as the presence of del(17p) combined with a TP53 mutation or at least two TP53 mutations, was analyzed in a real-world cohort of 204 patients. The results demonstrate that patients harboring multi-hit TP53 exhibit the poorest progression-free survival and overall survival compared with other high-risk cytogenetic groups and standard-risk patients. Multi-hit TP53 was associated with advanced disease stage and treatment resistance, highlighting its role as a critical adverse prognostic factor. These findings support the routine assessment of TP53 abnormalities for improved risk stratification and therapeutic decision-making in multiple myeloma.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10601 - Cell biology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

MOLECULAR MEDICINE

ISSN

1076-1551

e-ISSN

1528-3658

Svazek periodika

32

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

3

Kód UT WoS článku

001654157200001

EID výsledku v databázi Scopus

2-s2.0-105026628843